C Duez1, A Tomkinson, L D Shultz, D L Bratton, E W Gelfand. 1. Division of Cell Biology, Department of Pediatrics, National Jewish Medical and Research Center, Denver; and the Jackson Laboratory, Bar Harbor.
Abstract
BACKGROUND: In asthma, persistent inflammation might be the result of (1) an impaired ability to clear inflammatory cells from the airways and/or (2) impaired apoptotic responses. OBJECTIVE: In a mouse model, we investigated the regulatory role of Fas (CD95)-induced apoptosis in the development and resolution of airway inflammation and airway hyperresponsiveness (AHR). METHODS: Mice that were either Fas-sufficient (wild-type; WT) or Fas-deficient (lpr ) were sensitized by intraperitoneal injections of ovalbumin (OVA) and challenged once intranasally with OVA (IP-IN mice). Control (IN) mice were challenged only. RESULTS: IP-IN WT mice developed AHR at 48 hours; changes in airway resistance resolved by 96 hours. Airway responsiveness at 48 hours in IP-IN lpr mice was similar to that in IP-IN WT mice. However, in contrast to WT mice, IP-IN lpr mice sustained significant AHR at 96 hours in comparison with IN lpr mice; the AHR resolved by 6 days. Bronchoalveolar lavage fluid cell composition was similar in all of the different groups at 48 hours and 96 hours. Both IP-IN WT mice and lpr mice exhibited similar tissue eosinophilia, whereas IP-IN lpr mice had significantly lower numbers of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells in comparison with IP-IN WT mice at 48 hours. Anti-IL-5 antibody given to IP-IN lpr mice 48 hours and 72 hours after the challenge significantly decreased AHR and eosinophilic inflammation and increased TUNEL-positive cell numbers at 96 hours. CONCLUSION: These results suggest that Fas expression can regulate the onset and resolution of AHR through an increase in eosinophil apoptosis.
BACKGROUND: In asthma, persistent inflammation might be the result of (1) an impaired ability to clear inflammatory cells from the airways and/or (2) impaired apoptotic responses. OBJECTIVE: In a mouse model, we investigated the regulatory role of Fas (CD95)-induced apoptosis in the development and resolution of airway inflammation and airway hyperresponsiveness (AHR). METHODS:Mice that were either Fas-sufficient (wild-type; WT) or Fas-deficient (lpr ) were sensitized by intraperitoneal injections of ovalbumin (OVA) and challenged once intranasally with OVA (IP-IN mice). Control (IN) mice were challenged only. RESULTS:IP-IN WTmice developed AHR at 48 hours; changes in airway resistance resolved by 96 hours. Airway responsiveness at 48 hours in IP-IN lpr mice was similar to that in IP-IN WTmice. However, in contrast to WT mice, IP-IN lpr mice sustained significant AHR at 96 hours in comparison with IN lpr mice; the AHR resolved by 6 days. Bronchoalveolar lavage fluid cell composition was similar in all of the different groups at 48 hours and 96 hours. Both IP-IN WTmice and lpr mice exhibited similar tissue eosinophilia, whereas IP-IN lpr mice had significantly lower numbers of TdT-mediated dUTP nick end labeling (TUNEL)-positive cells in comparison with IP-IN WTmice at 48 hours. Anti-IL-5 antibody given to IP-IN lpr mice 48 hours and 72 hours after the challenge significantly decreased AHR and eosinophilic inflammation and increased TUNEL-positive cell numbers at 96 hours. CONCLUSION: These results suggest that Fas expression can regulate the onset and resolution of AHR through an increase in eosinophil apoptosis.
Authors: Minyong Chen; Akhil Hegde; Yeon Ho Choi; Barbara S Theriot; Richard T Premont; Wei Chen; Julia K L Walker Journal: Am J Respir Cell Mol Biol Date: 2015-09 Impact factor: 6.914
Authors: S K Sharma; F A Almeida; S Kierstein; L Hortobagyi; T Lin; A Larkin; J Peterson; H Yagita; J G Zangrilli; A Haczku Journal: Allergy Date: 2011-12-17 Impact factor: 13.146
Authors: Christina A Christianson; Nicholas P Goplen; Iram Zafar; Chaoyu Irvin; James T Good; Donald R Rollins; Balachandra Gorentla; Weimin Liu; Magdalena M Gorska; HongWei Chu; Richard J Martin; Rafeul Alam Journal: J Allergy Clin Immunol Date: 2015-01-21 Impact factor: 10.793
Authors: Jiankun Tong; Bryan S Clay; Caroline M Ferreira; Hozefa S Bandukwala; Tamson V Moore; Kelly M Blaine; Jesse W Williams; Lisa M Hoffman; Kimm J Hamann; Rebecca A Shilling; Joel V Weinstock; Anne I Sperling Journal: Am J Respir Cell Mol Biol Date: 2009-10-23 Impact factor: 6.914
Authors: T Kodama; K Kuribayashi; H Nakamura; M Fujita; T Fujita; K Takeda; A Dakhama; E W Gelfand; T Matsuyama; O Kitada Journal: Clin Exp Immunol Date: 2003-02 Impact factor: 4.330
Authors: Jiankun Tong; Hozefa S Bandulwala; Bryan S Clay; Robert A Anders; Rebecca A Shilling; Diwakar D Balachandran; Bohao Chen; Joel V Weinstock; Julian Solway; Kimm J Hamann; Anne I Sperling Journal: J Exp Med Date: 2006-04-17 Impact factor: 14.307